Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-β-cyclodextrin

Pharmazie

Volumn 63, Issue 11, 2008, Pages 796-805

  Van Der Schoot, S C ^a   Vainchtein, L D ^a   Nuijen, B ^a   Gore, A ^b   Mirejovsky, D ^b   Lenaz, L ^b   Beijnen, J H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Spectrum Pharmaceuticals   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; APAZIQUONE; BICARBONATE; TROMETAMOL;

ARTICLE; DRUG DEGRADATION; DRUG IDENTIFICATION; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BETA-CYCLODEXTRINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; INDOLEQUINONES; MASS SPECTROMETRY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 56749171102     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8168     Document Type: Article

References (10)

1. Beijnen JH, Fokkens RH, Rosing H, Underberg WJM (1986) Degradation of mitomycin C in acid phosphate and acetate buffer solutions. Int J Pharm 32: 111-121.
2. Beijnen JH, Hartigh J den, Underberg WJM (1985a) Qualitative aspects of the degradation of mitomycins in alkaline solution. J Pharm Biomed Anal 3: 71-79.
3. Beijnen JH, Hartigh J den, Underberg WJM (1985b) Quantitative aspects of the degradation of mitomycin C in alkaline solution. J Pharm Biomed Anal 3: 56-69.
4. Bekers O, Beijnen JH, Klein Tank MJT, Bult A, Underberg WJM (1991) Effect of cyclodextrins on the chemical stability of mitomycins in alkaline solution. J Pharm Biomed Anal 9: 1055-1060.
5. Fujimura K, Ueda T, KHagawa M, Takayanagi H, Ando T (1986) Reversed-phase retention behavior of aromatic compounds involving beta-cyclodextrin inclusion complex formation in the mobile phase. Anal Chem 58: 2668-2674.
6. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar RE, Fiebig HH, Double JA (1993) EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906.
7. Jonkman-de Vries JD, Kettenes-van den Bosch JJ, Henrar REC, Bult A, Beijnen JH (1996) Purity determinations in the bulk drug of the novel indolquinone antitumor agent EO9. Invest New Drugs 14: 181-191.
8. Jonkman-de Vries JD, Talsma H, Henrar REC, Kettenes-van den Bosch JJ, Bult A, Beijnen JH (1994) Pharmaceutical formulation development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. Cancer Chemother Pharmacol 34: 416-422.
9. Jonkman-de Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH (1993) A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9. Int J Pharm 100: 181-188.
10. Paz MM, Kumar GS, Glover M, Waring MJ, Tomasz M. (2004) Mitomycin dimers: polyfunctional cross-linkers of DNA. J Med Chem 47: 3308-3319.